Proof-of-concept study for SAR445088 in chronic inflammatory demyelinating polyneuropathy (CIDP)

Trial Identifier: PDY16744
Sponsor: Bioverativ, a Sanofi Company
Start Date: April 2021
Primary Completion Date: October 2025
Study Completion Date: October 2025
Condition: Neurological & Brain - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
CANADA, Quebec Gatineau, Quebec, CANADA, J8Y 1W2
CANADA, Quebec Quebec, CANADA, G1J 1Z4
CHINA Fuzhou, CHINA, 350001
CHINA Shanghai, CHINA, 200040
CHINA Wuhan, CHINA, 430030
FRANCE Bordeaux, FRANCE
FRANCE GARCHES, FRANCE, 92380
FRANCE Kremlin Bicetre, FRANCE, 94275
FRANCE MARSEILLE, FRANCE, 13385
FRANCE Nice Cedex, FRANCE, 06002
GERMANY Düsseldorf, GERMANY, 40225
GERMANY Essen, GERMANY, 45147
GERMANY Göttingen, GERMANY, 37075
GERMANY Tübingen, GERMANY, 72076
ITALY, Genova Genova, ITALY, 16132
ITALY, Lazio Roma, Lazio, ITALY, 00168
ITALY, Milano Milano, ITALY, 20132
ITALY, Milano Rozzano, Milano, ITALY, 20089
NETHERLANDS Amsterdam, NETHERLANDS, 1105AZ
NETHERLANDS UTRECHT, NETHERLANDS, 3584 CX
POLAND, Lubelskie Lublin, Lubelskie, POLAND, 20-954
SERBIA Belgrade, SERBIA, 11000
SERBIA Nis, SERBIA, 18000
SPAIN, Barcelona [Barcelona] Barcelona, Barcelona [Barcelona], SPAIN, 08041
SPAIN, Barcelona [Barcelona] Barcelona, Barcelona [Barcelona], SPAIN, 08035
SPAIN, Valencia Valencia, SPAIN, 46026
UNITED STATES, California Los Angeles, California, UNITED STATES, 90033
UNITED STATES, California Orange, California, UNITED STATES, 92868
UNITED STATES, Kansas Fairway, Kansas, UNITED STATES, 66205
UNITED STATES, Minnesota Minneapolis, Minnesota, UNITED STATES, 55414
UNITED STATES, New York New York, UNITED STATES, 10032